Table II. New relevant mutations in acute myeloid leukaemia.

ASXL1, Additional sex comb-like 1; CBF, core-binding factor; CEBPA, CCAAT/enhancer-binding protein alpha; CN-AML; cytogenetically normal acute myeloid leukaemia; DNMT3A, DNA methyl-transferase 3A; FLT3 ITD, Fms-related tyrosine kinase 3-internal tandem duplications; FLT3 TKD, Fms-related tyrosine kinase 3-tyrosine kinase domain; IDH1 and IDH2, Isocitrate dehydrogenase 1,2; KIT, CD117; MLL PTD, mixed lineage leukaemia partial tandem duplication; NPM1, nucleophosmin 1; PRC2, polycomb repressive complex 2; RAS, RAS viral (v-ras) oncogene homologue; RUNX1, Runt-related transcription factor 1; TET2, ten-11 translocation 2